Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose by Renia, Laurent, Goh, Yun Shan, Rouers, Angeline, Bert, Nina Le, Chia, Wan Ni, Chavatte, Jean-Marc, Fong, Siew-Wai, Chang, Zi Wei, Zhuo, Nicole Ziyi, Tay. Matthew Zirui, Chan, Yi-Hao, Tan Chee Wah, Yeo, Nicholas Kim-Wah, Amrun, Siti Naqiah, Huang, Yuling, Wong, Joel Xu En, Hor, Pei Xiang, Loh, Chiew Yee, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd Salleh, Carissimo, Guillaume, Dowla, Samanzer, Lim, Alicia Jieling, Zhang, Jinyan, Lim, Joey Ming Er, Wang, Cheng-I., Ding, Ying, Pada, Surinder, Sun, Lousia Jin, Somani, Jyoti, Lee, Eng Sing, Ong, Desmond Luan Seng, Leo, Yee-Sin, MacAry, Paul A., Lin, Raymond Tzer Pin, Wang, Lin-Fa, Ren, Ee Chee, Lye, David C., Bertoletti, Antonio, Young, Barnaby Edward, Ng, Lisa F. P., Ruesta, Torres Anthony, Neo, Vanessa, Chen, Wendy Yehui, Goh, Estelle Yi Wei, Ong, Alice Soh Meoy, Chua, Adeline Chiew Yen, Nguee, Samantha Yee Teng, Tan, Yong Jie, Tang, Weiyi

Subjects: Get full text

Dengue vaccines : dawning at last? by Wilder-Smith, Annelies

“…The need for a dengue vaccine is more pressing than ever. Dengue—a mosquito-borne viral infection caused by any of the four dengue virus serotypes—is regarded as the most important arboviral disease globally, because more than 50% of the world's population live in regions at risk of the disease, and evidence points towards further geographical and numerical expansion.1 The results of Maria Capeding and colleagues' multicentre phase 3, randomised, observer-masked, placebo-controlled efficacy trial2 for a recombinant, chimeric, live attenuated tetravalent dengue vaccine (CYD-TDV), in The Lancet, have been awaited with great anticipation paired with some trepidation, on the basis of the disappointing results from a previous single-centre trial with the same vaccine in Thailand.…”
Get full text
Get full text

The way forward after COVID-19 vaccination : vaccine passports with blockchain to protect personal privacy by Tsoi, Kelvin K. F., Sung, Joseph Jao Yiu, Lee, Helen W. Y., Yiu, Karen K. L., Fung, Hong, Wong, Samuel Y. S.

“…Stepping into 2021, more COVID-19 vaccines are becoming accessible in the global market. …”
Get full text

Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies by Young, Barnaby, Sadarangani, Sapna, Jiang, Lili, Wilder-Smith, Annelies, Chen, Mark I-Cheng

Subjects: Get full text
Get full text

Determining the prevalence and correlates of COVID-19 booster vaccine hesitancy in the Singapore population following the completion of the primary vaccination series by Tan, Kevin Y. K., Soh, Alexius S. E., Ong, Brenda W. L., Chen, Mark IC, Griva, Konstadina

Subjects: Get full text

Low antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees by Velumani, Sumathy, Toh, Ying Xiu, Balasingam, Shobana, Archuleta, Sophia, Leo, Yee Sin, Gan, Victor C., Thein, Tun Linn, Wilder-Smith, Annelies, Fink, Katja

Subjects: Get full text
Get full text

Edging closer towards the goal of a dengue vaccine by Wilder-Smith, Annelies, Yoon, In-Kyu

Subjects: Get full text
Get full text

Zika vaccines and therapeutics: landscape analysis and challenges ahead by Wilder-Smith, Annelies, Vannice, Kirsten, Durbin, Anna, Hombach, Joachim, Thomas, Stephen J., Thevarjan, Irani, Simmons, Cameron P.

Subjects: “…Zika Vaccines…”
Get full text
Get full text

COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore by Zhang, Zewen, Nur Diana Binte Ishak, Que, Frances Victoria Fajardo, Chua, Zi Yang, Chan, Sock Hoai, Chiang, Jianbang, Ngeow, Joanne

Subjects: Get full text

COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore by Yeo, Tianrong, Siew, Rachel Wan En, Gulam, Muhammad Yaaseen, Tye, Janis Siew Noi, Aw, Amelia Yun Yi, Sivalingam, Thanushiree, Peng, Xuejuan, Yong, Kok Pin, Saffari, Seyed Ehsan, Chao, Yinxia, Tan, Kevin

Subjects: Get full text

Moving forward with Takeda's live chimeric tetravalent dengue vaccine by Wilder-Smith, Annelies

Subjects: Get full text
Get full text

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine by Wilder-Smith, Annelies, Massad, Eduardo

Subjects: Get full text
Get full text

The public health value of vaccines beyond efficacy: methods, measures and outcomes by Wilder-Smith, Annelies, Longini, I., Zuber, P. L., Bärnighausen, T., Edmunds, W. J., Dean, N., Spicher, V. Masserey, Benissa, M. R., Gessner, B. D.

Subjects: “…Vaccine Efficacy…”
Get full text
Get full text

Severe thrombocytopenia, thrombosis and anti-PF4 antibody after Pfizer-BioNTech COVID-19 mRNA vaccine booster-Is it vaccine-induced Immune thrombotic thrombocytopenia? by Ling, Victor W. T., Fan, Eugene Bingwen, Lau, Soon Lee, Lee, Xiu Hue, Tan, Chuen Wen, Lee, Shir Ying

Subjects: Get full text

Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave by Goh, Yun Shan, Fong, Siew-Wai, Tay, Matthew Zirui, Rouers, Angeline, Chang, Zi Wei, Chavatte, Jean-Marc, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Tan, Yong Jie, Wang, Bei, Ngoh, Eve Zi Xian, Siti Nazihah Mohd Salleh, Lee, Raphael Tze Chuen, Lim, Georgina, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee-Sin, Lin, Raymond T. P., Lam, Meng Chon, Lye, David C., Young, Barnaby Edward, Ng, Lisa F. P., Renia, Laurent

Subjects: Get full text

Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-coV-2 vaccines with and without boosters in Singapore by Ng, Oon Tek, Marimuthu, Kalisvar, Lim, Nigel, Lim, Ze Qin, Thevasagayam, Natascha May, Koh, Vanessa, Chiew, Calvin J., Ma, Stefan, Koh, Mingshi, Low, Pin Yan, Tan, Say Beng, Ho, Joses, Maurer-Stroh, Sebastian, Lee, Vernon J. M., Leo, Yee Sin, Tan, Kelvin Bryan, Cook, Alex R., Tan, Chorh Chuan

“…Importance: Assessing booster effectiveness of COVID-19 mRNA vaccine and inactivated SARS-CoV-2 vaccine over longer time intervals and in response to any further SARS-CoV-2 variants is crucial in determining optimal COVID-19 vaccination strategies. …”
Get full text

Intranasal delivery of RIG-I agonist drives pulmonary myeloid cell activation in mice by Nair, Sajith, Wu, Yilun, Nguyen, Trinh Mai, Fink, Katja, Luo, Dahai, Ruedl, Christiane

Subjects: Get full text

Kawasaki disease following administration of 13-valent pneumococcal conjugate vaccine in young children by Yung, Chee Fu, Ma, Xiangmei, Cheung, Yin Bun, Oh, Bee Khiam, Soh, Sally, Thoon, Koh Cheng

Subjects: “…Pneumococcal Conjugate Vaccine…”
Get full text

Ocular inflammatory events following COVID-19 vaccination: a multinational case series by Testi, Ilaria, Brandão-de-Resende, Camilo, Agrawal, Rupesh, Pavesio, Carlos, VOIESG

“…Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. …”
Get full text

Rapid evaluation of vaccine booster effectiveness against SARS-CoV-2 variants by Cheng, Hoi Lok, Lim, Sing Mei, Jia, Huan, Chen, Ming Wei, Ng, Say Yong, Gao, Xiaohong, Somani, Jyoti, Sengupta, Sharmila, Tay, Dousabel M. Y., Chua, Patrina W. L., R, Abirami, Ling, Sharon Y. H., McBee, Megan E., Young, Barnaby Edward, Sikes, Hadley D., Preiser, Peter Rainer

“…Here, we have implemented the test to monitor individual nAb level against wild-type and variants of SARS-CoV-2 at various time points of vaccination, including post-second-dose vaccination and postbooster vaccination. …”
Get full text